Antibodies to VLA-1

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S388220, C530S387300, C435S326000

Reexamination Certificate

active

10474832

ABSTRACT:
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

REFERENCES:
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Hölzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4.
R. Briesewitz et al., “Expression of Native and Truncated Forms of the Human Integrin α1 Subunit,”J. Bio. Chem., 268:2989-2996 (1993).
A. R. de Fougerolles et al., “Regulation of Inflammation by Collagen-Binding Integrins α1β1 and α2β1 in Models of Hypersensitivity and Arthritis,”J. Clin. Invest., 105:721-729 (2000).
M. Fabbri et al., “A Functional Monoclonal Antibody Recognizing the Human alpha1-Integrin I-Domain,”Tissue Antigens, 48:47-51 (1996).
I. Bank et al., “Analysis of Recombinant Human α1 Integrin I-Domain with a Function-Blocking Monoclonal Antibody 1B3.1,”Isr. Med. Assoc. J., 2:19-20 (2000).
S.C.G. Brezinsky et al., “A Simple Method for Enriching Populations of Transfected CHO Cells for Cells of Higher Specific Productivity,”J. Immunol. Methods, 277:141-155 (2003).
H. T. Cook et al., “Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis,”Am. J. Pathol., 161:1265-1272 (2002).
T. O. Fischmann et al., “Crystallographic Refinement of the Three-Dimensional Structure of the FabD1.3-Lysozyme Complex at 2.5-Å Resolution,”J. Biol. Chem., 266:12915-12920 (1991).
M. A. Holmes et al., “Conformational Correction Mechanisms Aiding Antigen Recognition by a Humanized Antibody,”J. Exp. Med., 187:479-485 (1998).
A. Ianaro et al., “Anti-Very Late Antigen-1 Monoclonal Antibody Modulates the Development of Secondary Lesion and T-Cell Response in Experimental Arthritis,”Lab. Invest., 80:73-80 (2000).
M. Karpusas et al., “Crystal Structure of the α1β1 Integrin I Domain in Complex with an Antibody Fab Fragment,”J. Mol. Biol., 327:1031-1041 (2003).
Y. Li et al., “Three-Dimensional Structures of the Free and Antigen-Bound Fab from Monoclonal Antilysozyme Antibody HyHEL-63,”Biochemistry, 39:6296-6309 (2000).
N. S. Sampson et al., “Global Gene Expression Analysis Reveals a Role for the α1Integrin in Renal Pathogenesis,”J. Biol. Chem., 276:34182-34188 (2001).
E.T. Baldwin et al.,“Cation Binding to the Integrin CD11b I Domain and Activation Model Assessment,”Structure,6:923-935 (1998).
R. Briesewitz et al., “Expression of Native and Truncated Forms of the Human Integrin α1Subunit,”J. Biol. Chem., 268:2989-2996 (1993).
P. Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992).
C. Chothia et al., “Conformations of Immunoglobulin Hypervariable Regions,”Nature, 342:877-883 (1989).
M.S. Co et al., “Humanized Antibodies for Antiviral Therapy,”Proc. Nat. Acad. Sci. USA, 88:2869-2873 (1991).
A.L. Corbi et al., “The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) α Subunit,”J. Biol. Chem., 263:12403-12411 (1988).
A.L. Corbi et al., “cDNA Cloning and Complete Primary Structure of the α Subunit of a Leukocyte Adhesion Glycoprotein, P150,95,”EMBO J., 6:4023-4028 (1987).
D. Cosgrove, et al., “Integrin α1β1 and Transforming Growth Factor-β1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy,”Am. J. Path., 157:1649-1659 (2000).
D.R. Davies and G.H. Cohen, “Interactions of Protein Antigens with Antibodies,”Proc. Natl. Acad. Sci. USA, 93:7-12 (1996).
A.R. de Fougerolles et al., “Global Expression Analysis of Extracellular Matrix-Integrin Interactions in Monocytes,”Immunity, 13:749-758 (2000).
C.P. Edwards et al., “Identification of Amino Acids in the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecule-1 (ICAM-1)”,J. Biol. Chem., 270, 12635-12640 (1995).
C. Eigenbrot et al., “X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2Antibody 4D5 and Comparison with Molecular Modeling,”J. Mol. Biol., 229:969-995 (1993).
J. Emsley et al., “Structural Basis of Collagen Recognition by Integrin α2β1,”Cell, 100:47-56 (2000).
J. Emsley et al., “Crystal Structure of the I Domain from Integrin α2β1,”J. Biol. Chem., 272:28512-28517 (1997).
J. Foote and G. Winter, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol., 224:487-499 (1992).
A.A. Gaspari and S.I. Katz, “Contact Hypersensitivity,”Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, New York. Section 4.2.1-4.2.5 (1991).
P.J. Gotwals et al., “Divalent Cations Stabilize the α1β1 Integrin I Domain,”Biochemistry, 38:8280-8288 (1999).
P.J. Gotwals et al., “The α1β1 Integrin Is Expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization,”J. Clin. Invest., 97:2469-2477 (1996).
M.H. Grayson et al., αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1),J. Exp. Med., 188:2187-2191 (1988).
L.L. Green et al., “Antigen-specific Human Monoclonal Antibodies From Mice Engineered With Human Ig Heavy and Light Chain YACs,”Nature Genetics, 7:13-21 (1994).
M.E. Hemler et al., “Very Late Activation Antigens on Rheumatoid Synovial Fluid T Lymphocytes: Association with Stages of T Cell Activation,”J. Clin. Invest., 78:696-702 (1986).
M.E. Hemler et al., “VLA-1: A T Cell Surface Antigen which Defines a Novel Late Stage of Human T Cell Activation,”Eur. J. Immunol., 15:502-508 (1985).
C. Huang and B.D. Stollar, “A Majority of Ig H Chain cDNA of Normal Human Adult Blood Lymphocytes Resembles cDNA for Fetal Ig and Natural Autoantibodies,”J. Immunol., 151:5290-5300 (1993).
B. Hurtrel et al., “Differen

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to VLA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to VLA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to VLA-1 will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3915492

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.